Welcome to the e-CCO Library!

P306: Faecal calprotectin is highly effective to detect endoscopic ulcerations in Crohn’s disease regardless of disease location
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Buisson1,2*, W.Y. Mak3,4, M.J. Andersen Jr4, D. Lei4, J. Pekow4, R.D. Cohen4, B. Pereira5, D.T. Rubin4

Created: Thursday, 21 February 2019, 9:14 AM
P306: MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects
Year: 2021
Source: ECCO'21 Virtual
Authors: Ray, A.(1);Cui, D.(2);Lee, D.(2);Mangada, M.M.(1);Jones, J.(2);Bain, G.(1);Traber, P.G.(3);Vrishabhendra, L.H.(4);Krzeski, P.W.(5);Vande Casteele, N.(6,7);Reardon, M.M.(8);Stern, T.P.(9);Soo, C.L.(10);Nguyen, H.(11);Rogers, B.N.(12);Linde, P.G.(13);
Created: Wednesday, 2 June 2021, 4:12 PM
P306: Serum tryptophan metabolites as a biomarker for disease severity in patients with IBD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Karakan, T.(1)*;Karatas, A.(2);Cindoruk, M.(2);Gulbahar, O.(3);
Created: Friday, 14 July 2023, 11:05 AM
P306: The real-life experience of vedolizumab efficacy and safety in ulcerative colitis: a prospective observational multicentre cohort study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Amiot*1, L. Peyrin-Biroulet2, C. Stefanescu3, J. C. Grimaud4, J. Filippi5, B. Pariente6, X. Roblin7, R. Altwegg8, D. Laharie9, P. Marteau10, A. Buisson11, C. Trang-Poisson12, S. Nancey13, G. Savoye14, S. Viennot15, H. Brixi-Benmansour16, F. Carbonnel17, Y. Bouhnik3

Created: Friday, 22 February 2019, 9:49 AM
P306: What is the impact of perianal disease on anorectal function and quality of life of IBD patients? A prospective observational study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Litta F.*1, Scaldaferri F.2, Parello A.1, Zinicola T.2, Gasbarrini A.2, Ratto C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P307 Colorectal neoplasia risk in patients with inflammatory bowel disease and serrated lesions
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. De Jong1, S. Vos2, I. Nagtegaal2, Y. van Herwaarden1, L. Derikx1, F. Hoentjen1

Created: Thursday, 30 January 2020, 10:12 AM
P307: Fecal Lactoferrin levels are stable during pregnancy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Koslowsky B., Livovsky D.M., Goldin E., Bar-Gil Shitrit A.

Created: Wednesday, 20 February 2019, 10:36 AM
P307: High frequency of Deep Infiltrating Endometriosis in patients with Inflammatory Bowel Disease: a nested case-control study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Neri, B.(1)*;Russo, C.(2);Mossa, M.(1);Martire, F.G.(2);Aikaterini, S.(2);Mancone, R.(1);Calabrese, E.(1);Rizzo, G.(3);Exacoustos, C.(2);Biancone, L.(1);
Created: Friday, 14 July 2023, 11:05 AM
P307: Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Wang, Z.(1);Verstockt, B.(2,3);Vermeire, S.(2,3);Sabino, J.(2,3);Ferrante, M.(2,3);Declerck, P.(1);Dreesen, E.(1,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P307: Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. Reinisch*1, P. Gibson2, W. J. Sandborn3, B. Feagan4, C. Marano5, R. Strauss5, J. Johanns5, H. Zhang5, L. Padgett5, O. J. Adedokun5, J.-F. Colombel6, J. Collins7, P. Rutgeerts8, D. Tarabar9

Created: Friday, 22 February 2019, 9:49 AM
P307: Study of the proteomic profile in patients with ulcerative colitis, its correlation with diagnosis and disease activity
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Ahmed1*, S. Badr El-Din1, D. Header1, P. Moez2, M. Ibrahim3

Created: Thursday, 21 February 2019, 9:14 AM
P307: The effect of COVID-19 infection and vaccination in patients with Inflammatory Bowel Disease and Irritable Bowel Syndrome.
Year: 2022
Source: ECCO'22
Authors: Sciberras, N.(1);Pisani, A.(2);Vassallo, C.(1);Zahra Bianco, E.(2);Ellul, P.(2);
Created: Friday, 11 February 2022, 3:52 PM
P307: The use of the patient safety form in patients with inflammatory bowel disease, can improve the low screening and starting HBV prophylaxis rates in real life
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Demir*1, E. Uçar2, M. M. Çelik2

Created: Friday, 22 February 2019, 9:41 AM
P308 The need for psychological and psychotherapeutic interventions in Austrian patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Kutschera1, T. Waldhör2, H.P. Gröchenig3, T. Haas4, H. Wenzl5, P. Steiner6, R. Koch7, T. Feichtenschlager8, G. Eckhardt9, A. Mayer10, A. Kirchgatterer11, O. Ludwiczek12, R. Platzer13, P. Papay14, J. Gartner15, H. Fuchssteiner16, P.G. Peters17, G. Reicht18, G. Moser1, C. Dejaco1, C. Primas1, G. Novacek1, W. Miehsler19, Austrian IBD Study Group (ATISG)

Created: Thursday, 30 January 2020, 10:12 AM
P308: A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: SOUL study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Saito, D.(1)*;Hirai, F.(2);Uchiyama, K.(3);Takagi, T.(3);Naito, Y.(4);Takatsu, N.(5);Tanabe, H.(6);Kishimoto, M.(7);Matsuura, M.(1);Miyoshi, J.(1);Watanabe, K.(8);Esaki, M.(9);Naganuma, M.(10);Hisamatsu, T.(1);
Created: Friday, 14 July 2023, 11:05 AM
P308: Continued statural growth In older adolescents and young adults with Crohn’s disease and ulcerative colitis beyond the time of expected growth plate closure
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Gupta1*, E. King2, C. Liu2, F. Sylvester3, D. Lee4, B. Boyle5, A. Trauernicht6, S. Chen2, J. Pratt2, R. Colletti7, ImproveCareNow Network

Created: Thursday, 21 February 2019, 9:14 AM
P308: Effectiveness and Safety of tofacitinib for the Treatment of Ulcerative Colitis: A Single-Arm Meta-analysis of Observational Studies
Year: 2021
Source: ECCO'21 Virtual
Authors: Macaluso, F.S.(1);Maida, M.(2);Ventimiglia, M.(1);Orlando, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P308: Predictors of loss of response to adalimumab therapy: the importance of therapeutic drug monitoring in inflammatory bowel diseases
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Z. Kurti*1, Z. Vegh1, M. Rutka2, L. Gonczi1, K. Farkas2, K. Gecse1, P. A. Golovics1, B. Szalay3, T. Molnar2, P. Lakatos1

Created: Friday, 22 February 2019, 9:49 AM
P308: Quadruple oral antibiotic treatment in refractory Paediatric Inflammatory Bowel Disease – incidence and analysis of responders from a 10 year cohort.
Year: 2022
Source: ECCO'22
Authors: Meredith, J.J.(1,2);Armstrong, K.(1);Russell, R.K.(1,2);Henderson, P.(1,2);Wilson, D.C.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P308: Safety of the given patency capsule in patients with Crohn's disease or suspected Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Silva M., Cardoso H., Peixoto A., Nunes A.C.-R., Marques M., Lopes S., Magro F., Macedo G.

Created: Wednesday, 20 February 2019, 10:36 AM